



**Accrufer® (ferric maltol)**  
Effective 03/01/2022

<b>Plan</b>	<input checked="" type="checkbox"/> MassHealth <input type="checkbox"/> MH UPPL <input type="checkbox"/> Commercial/Exchange	<b>Program Type</b>	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
<b>Benefit</b>	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		
<b>Specialty Limitations</b>	N/A		
<b>Contact Information</b>	<b>Specialty Medications</b>		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	<b>Non-Specialty Medications</b>		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	<b>Medical Specialty Medications (NLX)</b>		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
<b>Exceptions</b>	N/A		

**Overview**

Accrufer is indicated for the treatment of iron deficiency or iron deficiency anemia in adults.

**Coverage Guidelines**

Authorization may be reviewed for members new to AllWays Health Partners who are currently receiving treatment with Accrufer excluding when the product is obtained as samples or via manufacturer’s patient assistance programs.

**OR**

Authorization may be granted for members when ALL the following criteria are met, and documentation is provided:

1. The member has a diagnosis of iron deficiency
2. The member has paid claims or physician documented inadequate response or adverse reaction to **THREE** of the four oral iron products: ferrous fumarate, ferrous gluconate, ferrous sulfate or polysaccharide iron complex
3. The member has attempted strategies to improve tolerability of other iron products if gastrointestinal adverse events occurred has been attempted

**Continuation of Therapy**

Reauthorization will be granted when provider documents continuation of therapy and positive response to therapy.

**Limitations**

1. Initial approvals and reauthorizations will be granted for 24 months



### **References**

1. Accrufer (ferric maltol) [prescribing information]. Gateshead Quays, UK: Shield Therapeutics Inc; January 2021.
2. Centers for Disease Control and Prevention (CDC). Recommendations to prevent and control iron deficiency in the United States. *MMWR Recomm Rep*. 1998;47(RR-3):1-29.[\[PubMed 9563847\]](#)

### **Review History**

01/19/2022 – Created and Reviewed for Jan P&T. Matched with MH criteria. Effective 03/01/2022

### **Disclaimer**

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.